A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach
Kapoor S, Gupta N, Sharma A
Asian Pacific journal of cancer prevention : APJCP · 2 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- In vitro/mechanistic study (classified by our AI screen)
- Studied in
- Cells or lab samples
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Independent funding
- Government
- Ministry of AYUSH, Government of India
- Government
- Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2023-11-01 · Asian Pac J Cancer Prev · vol. 24 · issue 11 · pp. 3705–3714
- Publisher
- West Asia Organization for Cancer Prevention
- Cited
- 3 citations · more than 80% of similar papers · 0.9× the field average
- References
- 19 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Phytochemicals and Medicinal Plants · Food Science and Nutritional Studies · Humic Substances and Bio-Organic Studies
- Keywords
- Lenalidomide, Propidium iodide, Apoptosis, Multiple myeloma, Pharmacology, Annexin, Cytotoxicity, MTT assay, Chemistry, Cytotoxic T cell, Population, Medicine, Cancer research, Immunology, Biochemistry, In vitro, Programmed cell death
- MeSH
- humans, multiple myeloma, neoplasm recurrence, local, plant extracts, antineoplastic agents, carcinogenesis, lenalidomide
3 authors
From IN
- Shraddha KapoorAll India Institute of Medical Sciences
- Nidhi GuptaAll India Institute of Medical Sciences
- Alpana SharmaAll India Institute of Medical Sciences
Abstract
Background
The present study explored the molecular mechanism of herbal (Unani) drug Habb-e-asgandh as anti-tumorigenic adjuvant therapy experimentally in U266 cells and its role in treatment of Multiple myeloma. The formulation of Habb-e-asgandh is investigated alone or as a combinatorial therapy with standard drug lenalidomide to check for its efficacy against U266 myeloma cells for prevention of drug relapse and resistance.
Methods
We performed the following assays on singly or in combination of Habb-e-asgandh-Lenalidomide treated U266 cells. The cytotoxicity evaluation done by MTT assay, we studied cell cycle kinetics by Propidium Iodide staining, mitochondrial apoptosis analysis by Annexin V/PI dual staining and JC1 staining assays. Further, anti-oxidative potential was assessed by ORAC assay and cytokine levels estimation of anti-inflammatory (TNF-alpha and IL6) and anti-angiogenic (VEGF and Ang-2) markers were done by ELISA.
Results
The myeloma U266 cells when treated with Habb-e-asgandh alone or in combination with standard drug lenalidomide showed cytotoxicity in dose dependent manner with promising effects at 0.4 mg/ml (IC30) and 1.5 mg/ml (IC50) inhibitory concentrations. The formulation treated cells showed modulation in cell cycle kinetics patterned by sub Go/G1 population accumulation. Furthermore, it induced mitochondrial apoptosis mainly at half maximal inhibitory concentration and in combinatorial combinations. Significantly elevated oxidative capacities (p<0.05) and reduced levels of angiogenic and pro-inflammatory markers were observed. Multiple mechanism based inhibition by Habb-e-asgandh in co-treatment with lenalidomide against myeloma cells is indicated. Conclusion: Habb-e-asgandh formulation possess anti-tumorigenic efficacy against multiple myeloma. The adjunctive Habb-e-asgandh formulation with standard chemotherapeutic drug may prove to be a potent anti-myeloma agent in interventional therapy for Multiple myeloma if further studied in future avenues.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.